偏瘫肩痛(HSP)是脑卒中患者常见的并发症之一,严重影响患者的康复进程和生活质量。重复经颅磁刺激(repetitive transcranial magnetic stimulation,rTMS)作为一种无创的神经调控技术,已广泛用于治疗各种神经系统疾病。本文综述了rTMS的...偏瘫肩痛(HSP)是脑卒中患者常见的并发症之一,严重影响患者的康复进程和生活质量。重复经颅磁刺激(repetitive transcranial magnetic stimulation,rTMS)作为一种无创的神经调控技术,已广泛用于治疗各种神经系统疾病。本文综述了rTMS的作用机制及rTMS联合其他治疗对HSP患者的疼痛缓解、运动功能及生活质量改善等方面的潜在效益,以期为该类患者提供最佳的治疗策略,促进患者的身体康复。展开更多
随着医疗技术的不断进步和对转移性肾透明细胞癌(mRCC)认识的日渐深入,mRCC的治疗模式发生了显著转变。目前除手术外,mRCC的治疗主要采用靶向治疗和免疫治疗,在取得显著疗效同时也面临着耐药和无反应性等问题。为了解决这些问题,新技术...随着医疗技术的不断进步和对转移性肾透明细胞癌(mRCC)认识的日渐深入,mRCC的治疗模式发生了显著转变。目前除手术外,mRCC的治疗主要采用靶向治疗和免疫治疗,在取得显著疗效同时也面临着耐药和无反应性等问题。为了解决这些问题,新技术和药物的研发正在不断进行。本文将对mRCC的靶向及免疫治疗方式、探索性治疗方案及治疗趋势进行综述,并通过总结发现各项技术原理和适用人群的差异,认为联合治疗和精准治疗将成为未来发展的主要方向。在未来的研究中,重点将放在如何更好地综合利用不同治疗技术以及更精确地定位适用人群,以实现更有效的mRCC治疗。With the continuous advancement of medical technology and the deepening of the understanding of metastatic clear cell renal cell carcinoma (mRCC), the treatment mode of mRCC has undergone a significant transformation. At present, in addition to surgery, the treatment of mRCC mainly uses targeted therapy and immunotherapy, which has achieved remarkable efficacy but also faces problems such as drug resistance and non-responsiveness. In order to solve these problems, the research and development of new technologies and drugs is constantly underway. This article reviews the targeted and immunotherapy methods, exploratory treatment options and treatment trends of mRCC, and finds the differences in various technical principles and applicable populations, and believes that combination therapy and precision therapy will become the main direction of future development. In future research, the focus will be on how to better integrate different treatment technologies and more precisely target the appropriate population to achieve more effective mRCC treatment.展开更多
文摘偏瘫肩痛(HSP)是脑卒中患者常见的并发症之一,严重影响患者的康复进程和生活质量。重复经颅磁刺激(repetitive transcranial magnetic stimulation,rTMS)作为一种无创的神经调控技术,已广泛用于治疗各种神经系统疾病。本文综述了rTMS的作用机制及rTMS联合其他治疗对HSP患者的疼痛缓解、运动功能及生活质量改善等方面的潜在效益,以期为该类患者提供最佳的治疗策略,促进患者的身体康复。
文摘随着医疗技术的不断进步和对转移性肾透明细胞癌(mRCC)认识的日渐深入,mRCC的治疗模式发生了显著转变。目前除手术外,mRCC的治疗主要采用靶向治疗和免疫治疗,在取得显著疗效同时也面临着耐药和无反应性等问题。为了解决这些问题,新技术和药物的研发正在不断进行。本文将对mRCC的靶向及免疫治疗方式、探索性治疗方案及治疗趋势进行综述,并通过总结发现各项技术原理和适用人群的差异,认为联合治疗和精准治疗将成为未来发展的主要方向。在未来的研究中,重点将放在如何更好地综合利用不同治疗技术以及更精确地定位适用人群,以实现更有效的mRCC治疗。With the continuous advancement of medical technology and the deepening of the understanding of metastatic clear cell renal cell carcinoma (mRCC), the treatment mode of mRCC has undergone a significant transformation. At present, in addition to surgery, the treatment of mRCC mainly uses targeted therapy and immunotherapy, which has achieved remarkable efficacy but also faces problems such as drug resistance and non-responsiveness. In order to solve these problems, the research and development of new technologies and drugs is constantly underway. This article reviews the targeted and immunotherapy methods, exploratory treatment options and treatment trends of mRCC, and finds the differences in various technical principles and applicable populations, and believes that combination therapy and precision therapy will become the main direction of future development. In future research, the focus will be on how to better integrate different treatment technologies and more precisely target the appropriate population to achieve more effective mRCC treatment.
